Literature DB >> 20523017

Diagnosis of growth hormone deficiency.

E A Webb, M T Dattani.   

Abstract

The diagnosis of growth hormone deficiency (GHD) was essentially a clinical one prior to the advent of radioimmunoassay in the mid-1960s. From this point on both clinical and biochemical serum GH responses to a variety of provocation tests were used to define the condition. The definition of an adequate GH response to stimulation has changed over time, initially being <3 microg/l and gradually increasing to 10 microg/l. Over this period, GH assays became more sensitive and specific, and assays for IGF-1 and IGFBP-3 were developed. Detailed neuroimaging also became widely available and genetic aetiologies for GHD identified. Apart from a number of clear genetic causes for GHD, the diagnostic gold standard remains elusive. However, making the correct diagnosis has significant benefits to the child, guiding both future investigations and management. In this chapter we discuss the importance of taking into account all available evidence when making the diagnosis of GHD including clinical examination, detailed auxological measurements, bone age, molecular analysis, biochemical measures and neuroradiological assessment. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20523017     DOI: 10.1159/000316127

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  2 in total

1.  Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models.

Authors:  Urszula Smyczyńska; Joanna Smyczyńska; Maciej Hilczer; Renata Stawerska; Ryszard Tadeusiewicz; Andrzej Lewiński
Journal:  Endocr Connect       Date:  2017-12-14       Impact factor: 3.335

2.  Significance of Direct Confirmation of Growth Hormone Insensitivity for the Diagnosis of Primary IGF-I Deficiency.

Authors:  Joanna Smyczyńska; Urszula Smyczyńska; Maciej Hilczer; Renata Stawerska; Andrzej Lewiński
Journal:  J Clin Med       Date:  2020-01-16       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.